Review

The association between SARS-CoV-2 vaccines and transverse myelitis: A review

Fatima Naz Naeem, Syeda Fatima Saba Hasan, Muskaan Doulat Ram, Summaiyya Waseem *, Syed Hassan Ahmed, Taha Gul Shaikh

Dow University of Health Sciences, Karachi, Pakistan

ARTICLE INFO

Keywords:
Coronavirus
Neurological manifestation
Vaccine
Transverse myelitis

ABSTRACT

In late 2019, the emergence of a new viral strain, later referred to as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) took the shape of a global pandemic, affecting millions of lives and deteriorating economies around the globe. Vaccines were developed at an exceptional rate to combat the viral desolation, all of them being rolled out once they displayed sufficient safety and efficacy. However, assorted adverse events came into attention, one of them being Transverse Myelitis (TM), an infrequent, immune-mediated, focal disease of the spinal cord. This disorder can lead to severe neurological complications including autonomic, sensory, and motor deficits. The literature aims to shed light on TM and its various etiologies, specifically in line with the vaccine, and a comprehensive treatment plan. Discussing and reducing the number of vaccines related adverse events can help succor in bringing down the vaccine hesitancy and ultimately combatting the pandemic.

1. Introduction

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) which originated in Wuhan, China towards the end of 2019, was declared a pandemic by the World Health Organization (WHO) in March 2020 following its drastic spread [1]. To date, December 26, 2021, 276.4 million confirmed cases have been reported and 5.4 million deaths have occurred worldwide due to the virus [2]. Other than healthcare consequences, the detrimental economic implications of the pandemic have rendered numerous unemployed and financial markets and global economies unstable [3]. Furthermore, according to the United Nations Educational, Scientific and Cultural Organization (UNESCO), lockdowns and closures disrupted over half of the student population worldwide [4].

To overcome the debilitating effects of the virus, worldwide efforts led to the development of several COVID-19 vaccines within the first year of the pandemic. The currently authorized vaccines include (i) The viral vector vaccines comprising AstraZeneca, Sputnik, and Janssen incorporating spike protein gene into the Adenovirus DNA, which then induces the synthesis of anti-spike protein antibodies. (ii) modern technology-based RNA vaccines including Pfizer and Moderna directly delivering the messenger RNA code for spike protein [5]. The DNA and RNA vaccines use immunologic liposomes as delivery vehicles to obtain maximum antigen levels within the target cells [6,7]. (iii) Sinopharm and Sinovac which makes use of live attenuated virus to stimulate a protective immune response [8]. These vaccines employ adjuvants like Aluminum hydroxide to enhance their effects [6,9].

Despite having different modes of action, these vaccines were approved after rigorous trials and demonstrated an adequate safety profile [10]. As of December 26, 2022, 8.6 billion doses have been administered [2]. Injection site pain, headache, fever, chills, myalgias, and fatigue constitute the commonly reported adverse effects following vaccine administration. All these effects are mild, short-lived, and self-limited [11]. However, a few serious adverse events including tinnitus [12], vaccine-induced thrombotic thrombocytopenia (VITT) [13], myocarditis [14], uveitis [15], Guillain Barre Syndrome (GBS) [16] have also been reported. Although the current literature evidence the beneficial effects of COVID-19 vaccines in reducing hospital admissions and severe outcomes [17,18], rare side effects and spread of misinformation significantly continue to contribute toward vaccine hesitancy [19].

More recently, several cases of transverse myelitis have been...
reported following COVID-19 vaccination. According to Vaccine Adverse Event Reporting System (VAERS), 593 cases of TM following COVID-19 vaccination have been reported [20]. Although the incidence of these cases is rare, that is compared to the total vaccine doses administered (11.7 billion) [21]. Although the incidence of these cases is rare, understanding the precise pathophysiology, predispositions and management are integral towards countering vaccine hesitancy. In this review, we evaluate the currently available literature to highlight the potentially involved mechanisms and management of such cases.

2. Transverse myelitis: what we know about it?

Transverse myelitis (TM) is an infrequent, immune-mediated, focal disease of the spinal cord that may involve one or more levels, in the absence of a compressive lesion [22]. This form of acute inflammation leads to morbid changes in the spinal cord segments [23]. Around 1.8 million people are affected by this disease every year around the globe with maximal incidence reported between 20 and 40 years of age [24]. It is estimated that 3 in every 100,000 people suffer from this illness and about 66% of these have some degree of residual disability [25]. While the disease can result from a broad spectrum of etiologies, the most prevalent causes include demyelinating illnesses such as multiple sclerosis and neuromyelitis optica. It is also associated with infections like Herpes Simplex Virus (HSV), Varicella Zoster Virus (VZV), Epstein Barr Virus (EBV), and Cytomegalovirus (CMV), immunizations, neoplastic lesions, and connective tissue diseases [24]. Furthermore, numerous cases have been reported in individuals with systemic autoimmune conditions like systemic lupus erythematosus (SLE), Sjogren’s syndrome, etc [24,26]. Lastly, the cause of TM is unknown in up to 30% of cases [27]. It is clinically defined by the onset of acute or sub-acute motor, sensory, and autonomic dysfunction [24,28].

This disorder is known to cause neurological symptoms including autonomic, sensory, and motor deficits [23]. Paresthesia and numbness are initial symptoms among adults. Patients also complain of pain in the spinal region, extremities, and abdomen. Weakness is characterized by expeditious development of ascending paraparesis, starts in the lower limbs and then rapidly involves the upper extremities. The genitourinary system is greatly affected with diseased experiencing urinary incontinence, difficulty in voiding, increased urgency, erectile dysfunction, ejaculatory disorders, and markedly decreased lubrication in females. Pudendal nerve lesion diminishes the sensations in both men and women which makes orgasm arduous and causes sexual impairment. Involuntary bowel movements and constipation are the usual manifestations of the gastrointestinal system [29].

This disorder is classified based on the area and extent of the lesion, and the diagnosis is made using spinal cord imaging particularly magnetic resonance imaging (MRI) [30] and lumbar puncture with microscopic analysis of the cerebrospinal fluid (CSF) which identifies inflammatory markers, oligoclonal bands, specific proteins, and enzymes [31]. Longitudinally extensive transverse myelitis (LETM) is a type of TM that involves three or more vertebral segments and is associated with serious morbidity and increased risk for recurrence [32].

3. Literature search and data extraction

Three authors (FNN, SFSH, MDR) independently conducted a thorough literature search over PubMed and google scholar from inception till November 25, 2021. The following key terms separated by BOOL-EAN Operators ‘OR’ and ‘AND’ were employed: “SARS-CoV-2 vaccine”, “Coronavirus vaccine”, “COVID-19 vaccine”, “transverse myelitis”, “spinal cord inflammation”, “longitudinally extensive transverse myelitis”, “LETM”. Grey literature and bibliographies of the relevant articles were also screened without any restriction of location and language. Any discrepancies were resolved by discussion with a fourth author (SW). The results of the literature search are shown in Fig. 1. Following a comprehensive literature search, the retrieved full-length articles were screened and recruited for inclusion in this review. After study selection, two authors (SHA, TGS) independently tabulated all the

![Fig. 1. Prisma Flowchart](image-url)
6. Transverse myelitis following SARS-CoV-2 vaccines

The mechanism by which COVID-19 causes ATM is not well comprehended but has been presumed to be that of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1). SARS-CoV-1 was thought to cause extra-pulmonary manifestations through its functional receptor; ACE-2, which is abundantly expressed on the endothelial layer of blood vessels of all organs. Entrance to the nervous system can take place through two pathways: directly or indirectly. The direct pathway is via trans-synaptic transmission from the peripheral nervous system or by hematogenous spread into the blood-brain barrier (BBB) through ACE-2 [56]. Whilst the indirect pathway is through a systemic immune response, the combination of the high abnormal CSF protein test and acute inflammation of the spine observed from the MRI findings were confirmed evidence of acute transverse myelitis [33] after the administration of the SARS-CoV-2 vaccine in the cases under review.

7. Pathophysiology

Usually, TM’s pathogenesis involves an atypical immune response causing injury to the spinal cord. At times, infections result in the transcription of a protein that mimics the self-antigen which stimulates T-lymphocytes against the body’s own tissue, resulting in immune-mediated destruction. Similarly, the administration of vaccines can also induce the same response. When the body’s immune system cannot distinguish between foreign antigens and host antigens, it triggers autoimmunity which leads to the destruction of host cells [23,46,49]. The following mechanisms may induce autoimmunity in a person:

A. Molecular Mimicry

The concept of molecular mimicry implied to post-infection neurological disorder could be possible pathogenesis eliciting TM after SARS-CoV-2 vaccination. The proposed mechanism of the post-infection “Molecular Mimicry” suggests that microorganism epitope shares a similar structure to the host’s antigen. The cross-reaction between the epitope and self-antigen activates B lymphocyte and the bystander activation of T cells, which induces an immune response. This mechanism appears to be the explanation for vaccines with viral antigen adjuvants, which may mediate immune responses targeting spinal cords [23,24,29,37,50]. AZD1222 and Johnson & Johnson COVID-19 vaccines, both contain adenosine antigens, thus may induce acute TM by the same pathogenesis [24,51].

The mRNA vaccine consists of spike glycoprotein sequencing as their main target [52], hence the proposed mechanism of molecular mimicry in such vaccines can be cross-reactivity with a structurally similar host protein causing an acute autoimmune reaction [34,46]. A study reported massive commonality between the SARS-CoV-2 glycoprotein and human proteomes, thereby further supporting molecular mimicry as a possible pathogenesis mechanism [53].

B. Interaction between Spike Protein Antibody and Host Protein

The Moderna COVID-19 (mRNA-1273) vaccine is composed of an mRNA encoding the pre-fusion spike protein encapsulated in lipid nanoparticles, with no adjuvants [54]. Therefore, other mechanisms might be involved in the development of autoimmunity in such cases. A study suggested that the immunological reaction between the SARS-CoV-2 spike protein antibody and tissue proteins, such as myelin basic protein, maybe a plausible cause for the occurrence of demyelinating autoimmune diseases [36,55].

C. Role of Angiotensin-converting Enzyme 2 Receptors

It can be speculated that post-vaccination spike protein elicits a similar response in the body, as that of post-SARS-CoV-2 infection resulting in the development of TM via interaction of spike protein and angiotensin-converting enzyme 2 (ACE-2) receptors.

The mechanism by which COVID-19 causes ATM is not well comprehended but has been presumed to be that of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1). SARS-CoV-1 was thought to cause extra-pulmonary manifestations through its functional receptor; ACE-2, which is abundantly expressed on the endothelial layer of blood vessels of all organs. Entrance to the nervous system can take place through two pathways: directly or indirectly. The direct pathway is via trans-synaptic transmission from the peripheral nervous system or by hematogenous spread into the blood-brain barrier (BBB) through ACE-2 [56].
| Author          | Country   | Age Sex    | Past Medical History                                                                 | Vaccine Administered                                      | Presenting Complaint                                                                 | Clinical Findings                                                                 | Investigations and Diagnosis                                                                 | Treatment                                                                 | Outcome                                                                 |
|-----------------|-----------|------------|---------------------------------------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Tahir et al.    | USA       | 44 y/o     | Female Non-significant                                                                   | Ad26.COV2. S vaccine (Johnson & Johnson/Janssen) 10 days  | Back pain along with nausea and urinary retention for three days. Numbness and weakness in lower extremities along with fever, chills and body aches was also present. | Exaggerated (+3) deep tendon reflex in both extremities and positive Babinski sign bilaterally. Decreased vibration in bilateral toes, and mild paresis in neck and abdomen. | MRI showed increased signal throughout the spinal cord extending from the C2-C3 segment. Lumbar puncture showing WBC count of 227 μ/L and RBC count of 25 μ/L. A total cell count of 100 with 96% of lymphocytes, 3% of monocytes, and 1% of eosinophils. CSF chemistry revealed glucose of 71 mg/dL, protein of 43 mg/dL, albumin 0.6 g/dL and lactase dehydrogenase 8 units/L. The myelin basic protein was 2.8 mcg/L and IgG index was 0.67. | Plasma exchange for five treatments over ten days was started after the completion of three-day course of methylprednisolone | Discharged                                                               |
| Alshararni et al. | Saudi Arabia | 38 y/o     | Male History of lower extremities pain and numbness                                      | BNT162b2 mRNA-vaccine Pfizer 1 day after first dose.   | Pain and weakness in lower extremities along with severe headache                     | N/A                                                                                 | N/A                                                                                 | N/A                                                                       |                                   |
| McLean et al.   | USA       | 69 y/o     | Female Surgically treated cervical cancer, hypothyroidism, hyperlipidemia, restless leg syndrome, and right leg sciatica | BNT162b2 mRNA-vaccine Pfizer 3 days after first dose.  | Weakness and paresthesia bilaterally in hands                                         | Patient was afebrile on admission. There was bilateral weakened grip strength and finger extension. Reflexes | MRI of cervical spine revealed extensive T2 signal abnormalities mostly in anterior aspect and in mid-cord extending from C3-4 down to T2-3. Serum was positive for Coxsackie B5 with titer of 1:8, and Coxsackie B6 with titer of 1:16 (clinically insignificant) | Patient was treated with 1g per day of methylprednisolone for five days along with aggressive physical and occupational training. | Discharged                                                               |
| Khan et al.     | NA        | 67 y/o     | Female Known case of chronic kidney disease, coronary artery disease, neuropathy and previous colon rupture with colostomy | mRNA Vaccine Moderna 1 day after first dose.          | Tingling in right lower extremity and difficulty in ambulating requiring assistance for walking | Motor strength was low in right lower (3/5) and right upper (4/5). Upper motor neuron sign was bilaterally present in both lower extremities with +3 reflexes. | Hemoglobin was 8.5 g/dL (NR: 12.0–15.5 g/dL), hematocrit 27% (NR: 36–48%), platelet count 1,30,000 platelets/μL (150,000–450,000 platelets/μL). Calcium 8.4 mg/dL (8.6–10.3 mg/dL), total protein | IV solumedrol (IVMP) 1 g daily for 3 days but there was no improvement, so PLEX therapy were initiated for 5 days. | Discharged                                                               |

(continued on next page)
| Author          | Age Sex | Country     | Past Medical History          | Vaccine Administered Time from vaccination to onset of symptoms | Presenting Complaint                                      | Clinical Findings                                                                 | Investigations and Diagnosis | Treatment | Outcome  |
|-----------------|---------|-------------|--------------------------------|---------------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------|-----------|----------|
| Pagenkopf et al. | 45 y/o  | Germany     | Actinic dermatitis             | ChAdOx1 nCoV-19 (AstraZeneca) 11 days after first dose        | Babinski sign was also positive bilaterally along with marked loss of vibration in ankle. | 5.8 g/dL (6.8-8.3 g/dL), albumin 3.2 g/dL (3.4-5.4 g/dL). Creatinine was elevated to 1.32 mg/dL (0.7-1.2 mg/dL) and D-dimer elevated to 1.28 (range <0.5). Brain MRI revealed scattered patchy foci nonspecific for white matter signal change suggestive of chronic microvascular changes. MRI of the cervical spine revealed hyperintense lesions in the upper cervical spine and cord edema extending from C1-C3 with patchy post-contrast enhancement. CSF study revealed cell count 2, glucose 77 mg/dl, serum glucose 125 mg/dl, CSF protein 56 mg/dl, oligoclonal bands 2 in CSF and 2 in serum, with 0 isolated bands, IgG index 0.48 | MRI revealed a LETM lesion showing T2 hyperintense signal of the spinal cord with wide axial and longitudinal extent reaching from C3 to Th2 without gadolinium enhancement. The brain MRI was normal CSF analysis showed a predominantly polymorphonuclear pleocytosis of 481 cells/μl (67% granulocytes), increased protein (1.4 g/l), increased lactate (3.98 mmol/L) and decreased glucose (CSF/serum ratio 0.43). There was no evidence of intrathecal Ig-synthesis or unique oligoclonal bands in CSF. | The patient was given anti-infective combination therapy with acyclovir, ceftriaxone and ampicillin and additionally an anti-oedematous medication with 100 mg prednisolone IV. As soon as a specific infection of the spinal cord was excluded, a pulse treatment with high dose corticosteroids was initiated applying 1 g methylprednisolone per day for five consecutive days followed by oral tapering. | Discharged |          |
| Jian-Gao et al.  | 76 y/o  | Taiwan      | Hypertension and right sided hearing impairment | mRNA Vaccine Moderna 2 days after first dose | Low grade fever, right upper limb paresthesia that extended from the distal to the proximal limb areas, and to the right lower limb, progressive gait disturbance and sacral paresthesia | Exhibited good muscle strength, decreased proprioceptive sensation below the right T4 dermatome, impaired joint position sense and thermal analgesia in the right limbs. The deep tendon reflexes of the right limbs was | C-spine MRI revealed extensive intramedullary hyperintensity at C2-C5 levels on T2-weighted images, and at the C3 level with T1 ring enhancement of the cervical cord. Brain MRI and magnetic resonance angiography were unremarkable. Cerebrospinal fluid | Pulse therapy with intravenous methylprednisolone (1 g/day for five days). Following which, oral prednisolone (60 mg/day) was administered and then was gradually tapered off. Hydroxocobalamin (1 mg/day) was included in the regimen. | Discharged |          |

(continued on next page)
Table 1 (continued)

| Author       | Country       | Age | Sex   | Past Medical History                                      | Vaccine Administered Time from vaccination to onset of symptoms | Presenting Complaint                                                                 | Clinical Findings                                                                 | Investigations and Diagnosis                                                                 | Treatment                                                                 | Outcome       |
|--------------|---------------|-----|-------|----------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------|----------------|
| Hsiao et al. | Taiwan        | 41  | y/o   | male                                                    | Well controlled Diabetes                                      | relatively brisk and Babinski sign showed a right extensor plantar response       | (CSF) analysis showed mild pleocytosis (15/μL) with neutrophil predominance (73%) and increased protein levels (57.2 mg/dL). CSF RPR, TPPA, HIV, cytology, serum AQP4 antibodies were all negative. It also revealed a vitamin B12 deficiency at 131 pg/mL. The patient was diagnosed with LETM. | Pulse therapy with 1000 mg of methylprednisolone daily for 5 days, and tapered off as symptoms improved | Discharged     |
|              |               |     |       |                                                         | ChAdOx1 nCoV-19 (AstraZeneca) 2 weeks after first dose        | left peripheral facial palsy, a tingling sensation over T4 dermatome, progressive paresthesia below T4, lower-limb weakness | bilateral pinprick sensation loss below T4, decreased lower-limb muscle power, severe over left side, loss of joint position, and vibration over bilateral lower limbs, increased bilateral knee reflex | Contrast-enhanced MRI of the spine revealed intramedullary-enhancing lesion over the spinal cord at the T1 to T6 vertebral levels. CSF analysis demonstrated mild pleocytosis (WBC:11/μL, lymphocyte predominant: 100%) and mild elevated protein levels (44.3 mg/dL). | N/A           |               |
|              |               |     |       |                                                         | BNT162b2 mRNA-vaccine Pfizer 13 days after second dose       | lower extremity weakness and difficulty in walking, progressed upper extremity with numbness of both lower limbs | moderate decline in the power of all extremities, decrease fine sensation and pain stimuli in the lower extremity, increased tone with spasticity pattern, hyperreflexia with positive Babinski sign. | MRI represented an acute inflammation on the spine. CBC was unremarkable. Brucellosis titer was negative | N/A           |               |
|              | England       | 58  | y/o   | Male                                                   | Type 2 diabetes mellitus and pulmonary sarcoidosis diagnosed at the age of 32 years | Progressive numbness in lower limbs, allodynia up to chest level, genital dysesthesia, an episode of uritary incontinence | Hyperesthesia below T7, hyperreflexia in all four limbs, post-void urinary retention and normal cranial nerves. | Contrast MRI of the head and whole spine revealed an extensive T2 weighted hyperintense signal abnormality up to C1 level. Repeat images of the thoracic cord suggested flow voids. Cerebrospinal fluid (CSF) analysis revealed a raised protein of 1.68 g/L, lymphocytic pleocytosis and oligoclonal bands of an identical band pattern to that found in the serum. CT of the thorax showed calcified mediastinal lymph nodes, nodules distributed peri-lymphatically and within the pulmonary fissures. Subsequent CT – positron emission tomography (CT-PET) showed no evidence of fluorodeoxyglucose | intravenous methylprednisolone 1 g/day for 5 days followed by oral prednisolone at 60 mg/day, 5 days of plasma exchange (PLEX) after 10 days of steroid | Recovering    |

(continued on next page)
response that prompts the release of a cytokine storm, especially interleukin-6 (IL-6) [57,58]. Therefore, the inflammatory response triggered by the interaction between spike proteins and angiotensin-converting enzyme 2 (ACE-2) receptors present in endothelial cells of the blood-brain barrier or spinal neurons may be another possible mechanism of demyelination [36,51,59].

D. Factors predisposing to the development of Autoimmunity

The fact that not all individuals receiving the SARS-CoV-2 vaccine developed TM suggests a plausible role of predisposing factors in the development of autoimmunity. Following are some of the reported and suggested factors.

Table 1 (continued)

| Author          | Age | Sex    | Past Medical History | Vaccine Administered Time from vaccination to onset of symptoms | Presenting Complaint                          | Clinical Findings                                                                                      | Investigations and Diagnosis                                                                 | Treatment                                                                                      | Outcome        |
|-----------------|-----|--------|----------------------|----------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------|
| Wee Yong Tan et al. | 25 y/o | Female | Non-significant | ChAdOx1 nCoV-19 (AstraZeneca) 16 days after first dose | fever, myalgia of lower limbs with progressive bilateral weakness, urinary retention | Afebrile with normal vital signs, numbness, areflexia below the T8 spinal level, bilateral hyperreflexia of lower limbs with reduced power (3/5 proximally and distally), exaggerated deep tendon reflexes at the knees and ankles with upgoing plantar. | Gd-enhanced MRI revealed multi-segment T2-hyperintensities (T3-T5, T7-T8 and T11-L1), which showed variable cord enhancement post-contrast at T7-T8 lesions. CSF examination showed clear-appearing CSF with an elevated protein count of 546 mg/L (normal range: 150–400) and CSF glucose of 3.1 mmol/L (serum glucose of 5.6 mmol/L). Blood investigations revealed haemoglobin of 8.12 g/dL with total white cells of 8.12 x 10^3 μL (81% neutrophils and 15% lymphocytes) and platelets of 285 x 10^3 μL. ESR was 21 mm/h. Urine microscopy revealed the presence of leucocytes and bacteria. | Intravenous (IV) methylprednisolone 1000 mg daily for 5 days. IV cephradine covering for urinary tract infection for 5 days and subcutaneous enoxaparin for deep venous thrombosis prophylaxis. | Discharged                                                |
| Fitzsimmons et al. | 63 y/o M | Non-significant | mRNA Vaccine Moderna 1 day after second dose | sharp shooting pain from the buttocks down the legs into bottoms of the feet with greater severity in the left leg, pain in the lower legs and ankles, numbness of left calf, both ankles and both feet, unable to urinate, constipation. | Patient had left foot drop and brisk patellar and Achilles reflexes | Cervical and lumbar spines appear within normal limits. Increased T2 cord signal seen in the distal spinal cord and conus with questionable associated enhancement. MRI was repeated two days later of brain and few punctate T2/FLAIR signal hyperintensities in bilateral corona radiata, nonspecific were seen. CSF findings included glucose 74 mg/dL (40–75); total protein 37 mg/dL (15–45); cell count and differential normal; total nucleated cell count 3 | IVIG 0.5 g/kg on 10 Apr and 11 Apr (2 doses); Methylprednisolone IV 1 G/day 11–15 Apr (5 doses) followed by oral prednisone | Discharged                                                |
i. Genetic Predisposition

Individuals developing the SARS-CoV-2 vaccine-associated TM may have certain genetic mutations thereby making them susceptible to autoimmunity development [60,61]. A mutation in VPS37A has been reported in individuals with idiopathic transverse myelitis [62]. Similarly, post-vaccination TM may be associated with certain genetic mutations. However, further research is required to identify the genetic role.

ii. Environmental Triggers

Autoimmune diseases arise in genetically predisposed individuals but require an environmental trigger. Of the many potential environmental factors, infections are the most likely cause [60]. In a few discrete illnesses such as reactive arthritis, rheumatic fever, or hepatitis B virus (HBV) associated vasculitis, the inciting microbial agent is relatively well defined. Similarly, viral vaccines can be implicated as an environmental trigger or factor associated with the development of autoimmunity [63,64].

ii. Comorbidities

An underlying chronic disease or chronic inflammatory process can be correlated to the autoimmunity development in some individuals. Some of the cases reviewed in this study had chronic diseases including hypothyroidism, chronic kidney disease, coronary artery disease, pulmonary sarcoidosis, neuropathy, and atopic dermatitis. Moreover, two cases had a history of diabetes mellitus (DM) should not be ignored as a coincidence. However, the establishment of a potential link between DM and the development of the SARS-CoV-2 vaccine-associated TM needs more evidence and can be elucidated in future research.

However, further investigations are crucial to identify complex interactions between specific predisposing factors and underlying chronic diseases for TM development. Moreover, strong exploration is vital to establish links between the interaction of spike protein with ACE-2 receptors. Lastly, the development of transverse myelitis regardless of viral vector or mRNA vaccine supports the idea of spike protein as the key pathogenesis of SARS-CoV-2 vaccine-associated TM which can be elucidated further in future studies.

8. Diagnostic criteria

Owing to a broad differential for TM, reaching a terminating conclusion may be tricky. Hence, physicians are advised to search and devise a cost-effective strategy. This can be done via an extensive patient’s clinical history, thorough examination, CSF pleocytosis and magnetic resonance imaging (MRI) findings [65].

The Brighton Collaboration Encephalomyelitis guideline can be utilized to confirm whether the inflammation is of post-vaccine etiology. The Collaboration group designed a set case definition and diagnostic criteria for encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM), exemplified in Fig. 3, which can be applied in diverse health care settings and different geographical areas [66].

9. Treatment

A. Glucocorticoids

Transverse myelitis (TM) is an inflammatory disorder for which the first-line therapy is the administration of intravenous glucocorticoid [67]. They act by altering the gene expression of inflammatory mediators, thereby reducing their levels in the body, and suppressing the inflammation [68]. Nine of the included studies reported the administration of glucocorticoids, such as methylprednisolone, followed by oral prednisone in three of the studies [36,39,41]. The remaining two studies [33,38] did not report the treatment. Administration through intramuscular and intravenous routes is of great advantage as it surpasses the liver biotransformation and gastrointestinal symptoms that occur when given orally [69]. Five of the included studies reported the administration of intravenous methylprednisolone [23,36,39–41]. This route might also be preferred due to rapid action (onset of action is 1 h) in
associated with anaphylactic shock and disruption of electrolytes such as calcium and magnesium [71]. Most of the symptoms occurring are minor with urticaria and pruritus being the most common [72]. Hence, plasma exchange can be used safely with appropriate monitoring.

B. Plasma Exchange

The plasma exchange can also be initiated if the management by corticosteroids is not optimum [67]. It is the procedure to remove the abnormally located substances from the body such as the removal of cytokines or viral load from the body in COVID-19 [71]. This can be seen in 3 of the included studies [23,24,39], where this line of treatment was started after methylprednisolone. However, the plasma exchange is associated with anaphylactic shock and disruption of electrolytes such as calcium and magnesium [71]. Most of the symptoms occurring are minor with urticaria and pruritus being the most common [72]. Hence, plasma exchange can be used safely with appropriate monitoring.

C. Other medications

Patients with TM can be given rituximab or immunomodulatory therapy such as cyclophosphamide to prevent the resistant TM [22,74]. Rituximab or immunomodulatory therapy helps by decreasing the attacks of diseases such as transverse myelitis or preventing the occurrence of neuromyelitis optica, which is an inflammatory central nervous disease [75,76]. None of the studies, included in this review, reports the usage of these medications. This might be because of different presentations in each case and different genetic factors such as age and co-morbidities.

10. Other neurological manifestations

A wide spectrum of neurological manifestations, ranging from mild to moderate, following COVID-19 vaccines has been reported in the literature. Severe adverse events following immunization included facial nerve palsy [77,78], thrombotic complications [79], ischemic stroke [80], Guillain-Barre Syndrome [81], and cerebral venous thrombosis [82], among many others. Some of the numerous manifestations witnessed post-COVID-19 vaccination are illustrated in Fig. 4. Despite several case reports, the fact that COVID-19 vaccines are the causative agents of all the manifestations is yet to be proven, suggesting the potential need for large-scale collaborative trials and studies to determine the exact relationship between the vaccines and neurological manifestation.

11. Conclusion

This review highlights the potential pathophysiology and management of SARS-CoV-2 vaccine-induced transverse myelitis in light of the currently available literature. Despite a rare incidence, it is integral to elucidate its precise pathogenesis that may help redefine vaccine administration criteria to eliminate incidence. While corticosteroids remained the mainstay of treatment, there is an overwhelming need to evaluate other treatment options in terms of both short and long-term effects. Further research must emphasize on investigating the genetic and environmental predispositions, risk populations, economic diagnostic measures, and potential treatments options in order to combat vaccine hesitancy and ensure the success of the global vaccination program.

Sources of funding

N/A.

Ethical approval

Not required.

Consent

N/A.

Author contributions

F.N-N and S-F-S-H conceived the idea, F.N-N, S-F-S-H, M.D.R and S-W, retrieved the data, did write up of letter, and finally, S-H.A and T.G. S reviewed and provided inputs. All authors approved the final version of the manuscript.
Acknowledgments

Declaration of competing interest

Guarantor

Registration of research studies

1. Name of the registry:
2. Unique Identifying number or registration ID:
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

Guarantor

Summaiya Waseem, MBBS, Corresponding author.

Declaration of competing interest

N/A.

Acknowledgments

None.

References

[1] E. Mahase, Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and impact. https://click.endnote.com/viewer?doi=10.1136%2Fpmed.1036koken–WmZMfj5MzEiJ11W1jExMrzYyVm1qL0nXMmD2l8L.TL7e2eVIT65Nev0et7eZm25D6c. (Accessed 11 February 2022).

[2] WHO coronavirus (COVID-19) dashboard | WHO coronavirus (COVID-19). https://covid19.who.int/ . (Accessed 11 February 2022).

[3] M. Nicola, Z. Alsafi, C. Sohrabi, et al., The socio-economic implications of the coronavirus pandemic (COVID-19): a review, Int J Surg Lond Engl 78 (2020) 185, 2022). https://doi.org/10.1016/j.ijsu.2020.04.018 .

[4] T.W. West, C. Hess, B.A.C. Cree, Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies, Semin. Neurol. 32 (2012) 97–113, https://doi.org/10.1055/s-0032-1322586 .

[5] K. Hofman, G.N. Shenoy, V. Chak, S.V. Balu-Iyer, Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines, Immunol. Invest. 50 (2021) 743–779, https://doi.org/10.1080/09273948.2021.1904977 .

[6] A.K. Shrestha, M.A. Colantonio, et al., Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature, J. Neurol. (2021), https://doi.org/10.1007/s00415-021-10785-2 .

[7] N. Puri, E.A. Coomes, H. Haghbayan, K. Gunaratne, Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases, Hum. Vaccines Immunother. 16 (2020) 2586–2593, https://doi.org/10.1080/21655451.2020.1780846 .

[8] The vaccine adverse event reporting system (VAERS) request. https://wonder.cdc.gov/vaers.html . (Accessed 11 May 2022).

[9] R. Sakakibara, T. Hattori, K. Yasuda, T. Yamanishi, Micturition disturbance in COVID-19 patients, J Case Rep Intern Med 8 (2021), 002681, https://doi.org/10.12890/2021_002681 .

[10] Z.-P. Yan, M. Yang, C.-L. Lai, COVID-19 vaccines: a review of the safety and efficacy of current clinical trials, Pharm Basel Switz 14 (2021) 406, https://doi.org/10.3390/ph14050406 .

[11] A.F. Hernandez, D. Calina, K. Poulos, et al., Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol Rep 8 (2021) 871, https://doi.org/10.1080/20520139.2021.1032930 .

[12] S.J. Ahmed, T.G. Shaikh, S. Waseem, et al., Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: a narrative review, Ann Med Surg 73 (2022), 102988, https://doi.org/10.1016/j.jamsus.2021.102988, 2012.

[13] B. Singh, P. Kaur, L. Cedo, et al., COVID-19 mRNA vaccine and myocarditis, Eur J Case Rep Intern Med 8 (2021), 002681, https://doi.org/10.12890/2021_002681 .

[14] T. Hasan, M. Khan, F. Khan, G. Hamza, Case of Guillain-Barré syndrome following COVID-19 vaccine, BMJ Case Rep. 14 (2021) e243629, https://doi.org/10.1136/bcr-2021-243629 .

[15] Moghadam SM, Vlîches TN, Zhang K, et al The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv. https://doi.org/10.1101/2020.11.27 .20240051 .

[16] H.L. Moline, Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 Years — COVID-NET, 13 States, February–April 2021, MMWR Morb. Mortal. Wkly. Rep. 70 (2021), https://doi.org/10.15585/mmwr.mm7032e3 .

[17] Moghadam SM, Vlîches TN, Zhang K, et al The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv. https://doi.org/10.1101/2020.11.27 .20240051 .

[18] N. Puri, E.A. Coomes, H. Haghbayan, K. Gunaratne, Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases, Hum. Vaccines Immunother. 16 (2020) 2586–2593, https://doi.org/10.1080/21655451.2020.1780846 .

[19] N. Tahir, G. Koorapati, S. Prasad, et al., SARS-CoV-2 vaccination-induced thrombocytopenia following coronavirus vaccine: a case report and review of literature, J. Neurol. (2021), https://doi.org/10.1007/s00415-021-10785-2 .

[20] The vaccine adverse event reporting system (VAERS) request. https://wonder.cdc.gov/vaers.html . (Accessed 11 May 2022).

[21] Moghadam SM, Vlîches TN, Zhang K, et al The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv. https://doi.org/10.1101/2020.11.27 .20240051 .

[22] N. Puri, E.A. Coomes, H. Haghbayan, K. Gunaratne, Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases, Hum. Vaccines Immunother. 16 (2020) 2586–2593, https://doi.org/10.1080/21655451.2020.1780846 .

[23] H. Ritchie, E. Mathieu, L. Rodrés-Guirao, et al., Coronavirus Pandemic (COVID-19), Our World Data, 2020.

[24] T.W. West, C. Hess, B.A.C. Cree, Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies, Semin. Neurol. 32 (2012) 97–113, https://doi.org/10.1055/s-0032-1322586 .

[25] S.H. Ahmed, S. Waseem, et al., NMOSD: Neuromyelitis optica spectrum disorders; LETM: Longitudinally extensive transverse myelitis; CVST: Cerebral venous sinus thrombosis.

[26] A.F. Hernández, D. Calina, K. Poulos, et al., Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol Rep 8 (2021) 871, https://doi.org/10.1080/20520139.2021.1032930 .

[27] A. Bhat, S. Naguwa, G. Cheema, M.E. Gershwin, The epidemiology of transverse myelitis, Autoimmun. Rev. 9 (2010) A395, https://doi.org/10.1016/j.erv.2010.05.006 .

[28] R. Sakakibara, T. Hattori, K. Yasuda, T. Yamanishi, Micturition disturbance in COVID-19 patients, J Case Rep Intern Med 8 (2021), 002681, https://doi.org/10.12890/2021_002681 .

[29] T.W. West, C. Hess, B.A.C. Cree, Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies, Semin. Neurol. 32 (2012) 97–113, https://doi.org/10.1055/s-0032-1322586 .

[30] N. Tahir, G. Koorapati, S. Prasad, et al., SARS-CoV-2 vaccination-induced thrombocytopenia following coronavirus vaccine: a case report and review of literature, J. Neurol. (2021), https://doi.org/10.1007/s00415-021-10785-2 .

[31] Moghadam SM, Vlîches TN, Zhang K, et al The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv. https://doi.org/10.1101/2020.11.27 .20240051 .
